23.26
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
9.67%
196.87
|
179.52 | 181.10 | 168.92 | 168.57 |
| Cost Of Revenue |
17.57%
40.30
|
34.28 | 40.87 | 34.31 | 38.86 |
| Gross Profit |
7.81%
156.57
|
145.24 | 140.23 | 134.62 | 129.71 |
|
|
11.06%
154.23
|
138.88 | 131.73 | 132.63 | 269.24 |
| Benefits Costs and Expenses |
15.48%
196.30
|
169.99 | 183.03 | 160.22 | 307.43 |
| Costs And Expenses |
12.35%
194.53
|
173.15 | 172.60 | 166.93 | 308.10 |
| Operating Income/Loss |
63.22%
2.34
|
6.362 | 8.499 | 1.99 | -139.53 |
| Nonoperating Income/Loss |
155.95%
-1.769
|
3.162 | -10.43 | 6.716 | 0.671 |
| Income/Loss From Continuing Operations Before Tax |
94.00%
0.571
|
9.524 | -1.927 | 8.706 | -138.86 |
| Income Tax Expense/Benefit, Deferred |
146.38%
-3.744
|
8.072 | 0.752 | 1.397 | 1.115 |
| Income Tax Expense/Benefit |
126.05%
-1.066
|
4.092 | 2.92 | 3.894 | 4.61 |
| Income/Loss From Continuing Operations After Tax |
69.86%
1.637
|
5.432 | -4.847 | 4.812 | -143.47 |
|
|
69.86%
1.637
|
5.432 | -4.847 | 4.812 | -143.47 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
101.57%
-0.691
|
44.04 | 45.46 | 46.27 | 46.13 |
| Diluted Average Shares |
101.55%
-0.687
|
44.46 | 45.46 | 46.53 | 46.13 |
| Basic Earnings Per Share |
66.67%
0.04
|
0.12 | -0.11 | 0.10 | -3.11 |
| Diluted Earnings Per Share |
66.67%
0.04
|
0.12 | -0.11 | 0.10 | -3.11 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):